NEW YORK — Digital pathology firm Paige has signed an agreement making Epredia a global distributor of its full line of diagnostic imaging products, the companies said last week.
Under the terms of the deal, Epredia will distribute Paige's products, including its US Food and Drug Administration-cleared and CE-marked Paige Platform pathology image viewer and storage system, worldwide with exclusivity in Japan. Epredia will begin commercializing the products alongside its own in the US and EU beginning in the second quarter, the companies said.
Additional terms were not disclosed.
In mid-2020, Kalamazoo, Michigan-based Epredia signed on as a distributor of Lunaphore Technologies' LabSat Research tissue staining platform. Earlier this year, New York City-based Paige — a spinout of Memorial Sloan Kettering Cancer Center — raised $125 million in Series C funding.